Shots:

• The US FDA has issued a EUA for Actemra/RoActemra to treat COVID-19 in hospitalized adults & pediatric patients aged >2 yrs. who are receiving systemic corticosteroids & require supplemental oxygen- non-invasive or invasive mechanical ventilation- or ECMO
• The EUA is based on results from 4 controlled studies i.e COVACTA- EMPACTA- REMDACTA & RECOVERY that evaluates Actemra/RoActemra (IV) in 5-500+ hospitalized patients with COVID-19. The studies suggest that the therapy may improve outcomes in patients with no new safety signals identified
• Actemra/RoActemra is the 1st approved IL-6 receptor antagonist for patients with moderate-to-severe active RA

  Ref: Roche | Image: Roche